ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintTitle ChevronIcon Twitter
Pharmaceuticals

Samsung Biologics to make coronavirus antibody drug for US startup

Treatment set for clinical trials and mass production next year

Once the treatment is approved by health authorities, Samsung Biologics will shift to mass production next year. (Photo courtesy of the company)

SEOUL -- Samsung Biologics has reached an agreement to produce a potential coronavirus treatment on behalf of an American biotechnology startup, with output scaled up in 2021 pending clearance from health authorities.

Under the $362 million deal with Vir Biotechnology announced Friday, Samsung Biologics will manufacture antibody treatments that have received preliminary approval from the U.S. Food and Drug Administration. Clinical trials are set to begin within the year.

Samsung Biologics will shift to mass production at a facility in Incheon next year after the treatment is approved by health authorities in various countries. Citing the Trump administration's support, a company official said that "the high likelihood that Vir's treatment candidates will be approved for the coronavirus" led to the agreement.

Vir, whose investors include SoftBank Group and the Bill & Melinda Gates Foundation, listed on New York's Nasdaq market in October.

"Our expectation is that there will be a significant need around the world for antibody therapies," Vir CEO George Scangos said in Friday's announcement. "Accordingly, we are taking proactive steps to reserve large scale manufacturing capacity to be ready to move quickly with any of our antibody candidates that prove to be clinically safe and effective."

Spurred by the announcement, Samsung Biologics' stock rose 16.8% on Friday. The company's market capitalization ranks third in South Korea, at around 37 trillion won, behind Samsung Electronics and SK Hynix.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends October 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to Nikkei Asia has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more